全文获取类型
收费全文 | 129014篇 |
免费 | 9819篇 |
国内免费 | 3799篇 |
专业分类
耳鼻咽喉 | 1001篇 |
儿科学 | 2359篇 |
妇产科学 | 1810篇 |
基础医学 | 7096篇 |
口腔科学 | 2900篇 |
临床医学 | 15353篇 |
内科学 | 19138篇 |
皮肤病学 | 2365篇 |
神经病学 | 6493篇 |
特种医学 | 4111篇 |
外国民族医学 | 42篇 |
外科学 | 12469篇 |
综合类 | 18977篇 |
现状与发展 | 23篇 |
一般理论 | 2篇 |
预防医学 | 5552篇 |
眼科学 | 2110篇 |
药学 | 10995篇 |
88篇 | |
中国医学 | 11861篇 |
肿瘤学 | 17887篇 |
出版年
2024年 | 342篇 |
2023年 | 2311篇 |
2022年 | 4223篇 |
2021年 | 5714篇 |
2020年 | 5376篇 |
2019年 | 4764篇 |
2018年 | 4525篇 |
2017年 | 5001篇 |
2016年 | 5326篇 |
2015年 | 5086篇 |
2014年 | 9212篇 |
2013年 | 11713篇 |
2012年 | 7554篇 |
2011年 | 8060篇 |
2010年 | 6640篇 |
2009年 | 6097篇 |
2008年 | 5976篇 |
2007年 | 6365篇 |
2006年 | 5700篇 |
2005年 | 5094篇 |
2004年 | 4124篇 |
2003年 | 3711篇 |
2002年 | 3037篇 |
2001年 | 2692篇 |
2000年 | 2243篇 |
1999年 | 1764篇 |
1998年 | 1459篇 |
1997年 | 1226篇 |
1996年 | 1010篇 |
1995年 | 910篇 |
1994年 | 720篇 |
1993年 | 560篇 |
1992年 | 503篇 |
1991年 | 460篇 |
1990年 | 394篇 |
1989年 | 349篇 |
1988年 | 336篇 |
1987年 | 284篇 |
1986年 | 224篇 |
1985年 | 270篇 |
1984年 | 237篇 |
1983年 | 176篇 |
1982年 | 171篇 |
1981年 | 168篇 |
1980年 | 135篇 |
1979年 | 128篇 |
1978年 | 68篇 |
1977年 | 45篇 |
1976年 | 53篇 |
1975年 | 35篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
TRH、EGF及地塞米松促进未成熟胎肺组织分化及表面活性物质合成的研究 总被引:5,自引:3,他引:2
目的 比较TRH、EGF与地塞米松对未成熟胎肺形态发育及表面活性物质水平的影响。方法 在兔妊娠第22-24d或第24-26d分别用TRH、EGF或地塞米松母体静脉注射治病,通过光镜、图像分析及电镜等技术观察胎肺的形态结构,并检测胎肺的磷脂水平。结果 光镜下,TRH、EGF与地塞米松治疗组第25d及27d胎肺肺泡腔、肺泡间隔发育均明显好于对照组;EGF、TRH与地塞米松治疗组第27d胎肺的肺泡腔与肺泡间隔的面积比无明显差异。但EGF和TRH治疗组第25d胎肺的肺泡腔与肺泡间隔之比明显小于地塞米松治疗组。电镜下,三个治疗组第27d胎肺内含有板层体的Ⅱ型上皮细胞数量明显多于对照组,但各治疗组及对照组第25d的胎肺Ⅱ型上皮细胞胞浆内几乎未见明显板层体,相反胞浆内糖原含量却非常丰富。此外,三个治疗组27d胎肺的磷脂水平均明显高于对照组。结论 EGF、TRH及地塞米松在兔妊娠第24-26d母体治疗均能促进胎肺的形态发育和表面活性物质的合成,三种治疗方法对胎肺的影响程序无明显不同;在妊娠第22-24d治疗,地塞米松对胎肺形态结构的促进作用较EGF和TRH更明显,但三者对Ⅱ型上皮细胞分化及表面活性物质的合成均无明显影响。 相似文献
22.
YS Nagar S Singh V Sawlani L Pal K Dimri P Lal 《Journal of Medical Imaging and Radiation Oncology》2005,49(2):160-162
A rare case of an advanced primary broad ligament carcinoma is discussed, with a review of the literature regarding its incidence, presentation and management. This patient showed a complete response to adjuvant cisplatin-based chemotherapy following panhysterectomy and is presently without any evidence of disease, 15 months after completion of her treatment. 相似文献
23.
Rodica Pop-Busui Jiang Lu Neuza Lopes Teresa L. Z. Jones and the BARI D Investigators 《Journal of the peripheral nervous system : JPNS》2009,14(1):1-13
Abstract We evaluated the associations between glycemic therapies and prevalence of diabetic peripheral neuropathy (DPN) at baseline among participants in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial on medical and revascularization therapies for coronary artery disease (CAD) and on insulin-sensitizing vs. insulin-providing treatments for diabetes. A total of 2,368 patients with type 2 diabetes and CAD was evaluated. DPN was defined as clinical examination score >2 using the Michigan Neuropathy Screening Instrument (MNSI). DPN odds ratios across different groups of glycemic therapy were evaluated by multiple logistic regression adjusted for multiple covariates including age, sex, hemoglobin A1c (HbA1c), and diabetes duration. Fifty-one percent of BARI 2D subjects with valid baseline characteristics and MNSI scores had DPN. After adjusting for all variables, use of insulin was significantly associated with DPN (OR = 1.57, 95% CI: 1.15–2.13). Patients on sulfonylurea (SU) or combination of SU/metformin (Met)/thiazolidinediones (TZD) had marginally higher rates of DPN than the Met/TZD group. This cross-sectional study in a cohort of patients with type 2 diabetes and CAD showed association of insulin use with higher DPN prevalence, independent of disease duration, glycemic control, and other characteristics. The causality between a glycemic control strategy and DPN cannot be evaluated in this cross-sectional study, but continued assessment of DPN and randomized therapies in BARI 2D trial may provide further explanations on the development of DPN. 相似文献
24.
Psoriasis is a chronic inflammatory condition that often requires life-long treatment. Conventional therapies have not fully met the needs of psoriatic patients, because of limited efficacy, adverse effects with cumulative use, and patient inconvenience. In the past decade, biologic immunotherapies have become accepted treatments for psoriasis as a result of perceived efficacy and safety on the part of patients and practitioners. However, most data on these medications come from relatively limited short-term trials. In this review, we will focus on the available long-term data on the efficacy of the biologic agents. We will emphasize the strengths and weakness of the available data of the biologic agents that are Food and Drug Administration (FDA)-approved for the treatment of moderate to severe psoriasis (alefacept, efalizumab, * etanercept, infliximab, and adalimumab), with the inclusion of a newer agent currently under FDA evaluation (ustekinumab). 相似文献
25.
26.
27.
Joan M. Farrell Ida A. Shaw 《Journal of behavior therapy and experimental psychiatry》2009,40(2):317-328
This study tests the effectiveness of adding an eight-month, thirty-session schema-focused therapy (SFT) group to treatment-as-usual (TAU) individual psychotherapy for borderline personality disorder (BPD). Patients (N = 32) were randomly assigned to SFT-TAU and TAU alone. Dropout was 0% SFT, 25% TAU. Significant reductions in BPD symptoms and global severity of psychiatric symptoms, and improved global functioning with large treatment effect sizes were found in the SFT-TAU group. At the end of treatment, 94% of SFT-TAU compared to 16% of TAU no longer met BPD diagnosis criteria (p < .001). This study supports group SFT as an effective treatment for BPD that leads to recovery and improved overall functioning. 相似文献
28.
老年人隐裂牙综合治疗的临床分析 总被引:3,自引:0,他引:3
目的:评价老年人隐裂牙综合治疗的临床效果。方法:对114例隐裂牙进行综合治疗,1年后随访观察。结果:114颗隐裂牙中,根管治疗全冠修复的有效率为92.86%,充填治疗组有效率为87.5%。结论:综合治疗可以保留牙体组织并恢复咬合力,是老年人隐裂牙治疗较理想的方法。 相似文献
29.
30.
J. P. G. Kaajan 《Pharmacy World & Science》1989,11(4):112-117
The general management of patients with chronic obstructive pulmonary disease and asthma is discussed. Pathophysiological mechanisms of bronchial obstruction and inflammation are briefly described. The importance of preventive measures is emphasized. Medicine prescribed in chronic obstructive pulmonary disease and asthma, their relative place in treatment schedules and route of administration are reviewed. Finally, the importance of maximal bronchodilatation in exacerbations is stressed and the few indications for antibiotic treatment are discussed. 相似文献